CClinicalTrials.gg
Not yet recruitingNCT07599397Updated May 20, 2026

Evaluation of the Changes in Matrix Metalloproteinase-9 Levels With Salvadora Persica (Miswak) in Periodontal Fibroblasts and Gingival Crevicular Fluid in Patients With Periodontitis

An Early Phase 1 interventional study of Salvadora Persica Root and Toothbrushing in Stage II or Stage III Grade B Periodontitis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Cairo University · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

The study is conducted to evaluate the invitro effect of Salvadora persica (miswak) extract on periodontal fibroblasts production of matrix metalloproteinase-9 (MMP-9) and prostaglandin E2 (PGE2) and correlating the results to clinical outcomes and biomarkers by assessing the MMP-9 and PGE2 levels in gingival crevicular fluid by a randomized controlled clinical trial comparing the use of toothbrush as the control group with miswak chewing stick as a substitute to personal mechanical plaque control in patients with stage II or III grade B periodontitis.

Read the detailed description

Despite the clinical benefits mentioned, miswak use have been associated with some drawbacks such as clinical attachment loss; improper use of miswak over a long period can result in a risk of oral tissues injury. To date, there is a lack of comprehensive evidence-based literature to guide a safe and effective accepted practice that can subsequently be used as oral hygiene instructions for miswak users. Correlation between the in vitro and in vivo findings will be performed to evaluate the translational relationship between the effects of miswak on periodontal fibroblast inflammatory activity and the corresponding clinical and biomarker outcomes in patients with periodontitis. Matrix metalloproteinase-9 (MMP-9) and prostaglandin E2 (PGE2) levels obtained from periodontal fibroblast cultures will be compared with gingival crevicular fluid (GCF) MMP-9 and PGE2 levels and clinical periodontal parameters, including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque index (PI).

02

Conditions studied

  • Stage II or Stage III Grade B Periodontitis
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Stage II or III, grade B periodontitis

Exclusion criteria

Exclusion Criteria:

  • Have poor manual dexterity

    • Systemic condition that may affect healing
    • Administration of certain medications that may modify the outcomes
    • Smoking patients
    • Pregnant females
    • Periapical involvement in teeth
    • Habitual or experienced users of miswak chewing sticks
    • History of topical or systemic chemical plaque control during the past 6 months
    • History of periodontal surgery during the past 6 months
    • Local risk factor that interfere with accessibility for regular personal plaque control aids
05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Miswak group.

    The test group that will be assigned to use miswak chewing sticks for personal plaque

    Behavioral: Salvadora Persica Root

  • Experimental
    Toothbrush group

    The control group that will be assigned to use the toothbrush for personal plaque

    Behavioral: Toothbrushing

Interventions

  • BehavioralSalvadora Persica Root

    Miswak chewing sticks will be used as an alternative to the toothbrush

  • BehavioralToothbrushing

    Modified Bass technique will be employed

06

What researchers measure

Primary outcomes

  1. Matrix metalloproteinase-9 (MMP-9) level in gingival crevicular fluid (GCF)

    GCF will be collected at baseline and after 3 months to assess the MMP-9 level change by ELISA kit

    Time frame: 3 months

07

Study locations

1 site
  • Ahram Canadian University
    Giza, Egypt
    • Noha Shaaban Shams Shams, Associate professor · Contact · noha.shams@gmail.com · 01011459366
    • Marwa ElSayed Abbas ElSayed, Lecturer · Principal investigator
    • Noha Shaaban Shams, Associate professor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599397
Lead sponsor
Cairo University
Responsible party
Marwa El Sayed Abbas Ahmed (Lecturer of Oral Medicine and Periodontology, Ahram Canadian University, Cairo University) — Principal investigator
First posted
May 20, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
May 20, 2026

Study contacts

Marwa ElSayed Abbas ElSayed, PhD/Lecturer
Contact
marwah.elsayed2015@gmail.com
01092221005 ext. +02
Noha Shaaban Shams, Associate professor
study director · Ahram Canadian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion